BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Berentsen S. Complement Activation and Inhibition in Autoimmune Hemolytic Anemia: Focus on Cold Agglutinin Disease. Semin Hematol 2018;55:141-9. [PMID: 30032751 DOI: 10.1053/j.seminhematol.2018.04.002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Risitano AM. Therapeutic complement modulation for hematological diseases: Where we stand and where we are going. Semin Hematol 2018;55:113-7. [PMID: 30032746 DOI: 10.1053/j.seminhematol.2018.05.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Berentsen S. New Insights in the Pathogenesis and Therapy of Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia. Front Immunol 2020;11:590. [PMID: 32318071 DOI: 10.3389/fimmu.2020.00590] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
3 Liu J, Li Y. Thrombosis associated with mycoplasma pneumoniae infection (Review). Exp Ther Med 2021;22:967. [PMID: 34335909 DOI: 10.3892/etm.2021.10399] [Reference Citation Analysis]
4 Kamesaki T, Nishimura J, Wada H, Yu E, Tsao E, Morales J, Kanakura Y. Demographic characteristics, thromboembolism risk, and treatment patterns for patients with cold agglutinin disease in Japan. Int J Hematol 2020;112:307-15. [DOI: 10.1007/s12185-020-02899-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Skattum L. Clinical Complement Analysis-An Overview. Transfus Med Rev 2019;33:207-16. [PMID: 31672339 DOI: 10.1016/j.tmrv.2019.09.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
6 Berentsen S, Röth A, Randen U, Jilma B, Tjønnfjord GE. Cold agglutinin disease: current challenges and future prospects. J Blood Med 2019;10:93-103. [PMID: 31114413 DOI: 10.2147/JBM.S177621] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 5.3] [Reference Citation Analysis]
7 Jalink M, de Boer ECW, Evers D, Havinga MQ, Vos JMI, Zeerleder S, de Haas M, Jongerius I. Halting targeted and collateral damage to red blood cells by the complement system. Semin Immunopathol 2021. [PMID: 34191092 DOI: 10.1007/s00281-021-00859-8] [Reference Citation Analysis]
8 Yui JC, Brodsky RA. Updates in the Management of Warm Autoimmune Hemolytic Anemia. Hematology/Oncology Clinics of North America 2022. [DOI: 10.1016/j.hoc.2021.11.005] [Reference Citation Analysis]
9 Wang Z, Bo L, Xu Y, Liu H, Zhao Y. Features of serum complement C3 and C4 levels in autoimmune hemolytic anemia patients. Int J Lab Hematol 2021. [PMID: 33459487 DOI: 10.1111/ijlh.13469] [Reference Citation Analysis]
10 Broome CM, Cunningham JM, Mullins M, Jiang X, Bylsma LC, Fryzek JP, Rosenthal A. Increased risk of thrombotic events in cold agglutinin disease: A 10-year retrospective analysis. Res Pract Thromb Haemost 2020;4:628-35. [PMID: 32548562 DOI: 10.1002/rth2.12333] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
11 Sefland Ø, Randen U, Berentsen S. Development of Multiple Myeloma of the IgA Type in a Patient with Cold Agglutinin Disease: Transformation or Coincidence? Case Rep Hematol 2019;2019:1610632. [PMID: 30949369 DOI: 10.1155/2019/1610632] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
12 Patriquin CJ, Kuo KHM. Eculizumab and Beyond: The Past, Present, and Future of Complement Therapeutics. Transfus Med Rev 2019;33:256-65. [PMID: 31703946 DOI: 10.1016/j.tmrv.2019.09.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
13 Garred P, Tenner AJ, Mollnes TE. Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics. Pharmacol Rev 2021;73:792-827. [PMID: 33687995 DOI: 10.1124/pharmrev.120.000072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
14 Borchert C, Herman A, Roth M, Brooks AC, Friedenberg SG. RNA sequencing of whole blood in dogs with primary immune-mediated hemolytic anemia (IMHA) reveals novel insights into disease pathogenesis. PLoS One 2020;15:e0240975. [PMID: 33091028 DOI: 10.1371/journal.pone.0240975] [Reference Citation Analysis]
15 Röth A, Fryzek J, Jiang X, Reichert H, Patel P, Su J, Morales Arias J, Broome CM. Complement-mediated hemolysis persists year round in patients with cold agglutinin disease. Transfusion 2021. [PMID: 34813663 DOI: 10.1111/trf.16745] [Reference Citation Analysis]
16 Capecchi M, Ciavarella A, Artoni A, Abbattista M, Martinelli I. Thrombotic Complications in Patients with Immune-Mediated Hemolysis. J Clin Med 2021;10:1764. [PMID: 33919638 DOI: 10.3390/jcm10081764] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Tvedt THA, Steien E, Øvrebø B, Haaverstad R, Hobbs W, Wardęcki M, Tjønnfjord GE, Berentsen SA. Sutimlimab, an investigational C1s inhibitor, effectively prevents exacerbation of hemolytic anemia in a patient with cold agglutinin disease undergoing major surgery. Am J Hematol 2022;97:E51-4. [PMID: 34778998 DOI: 10.1002/ajh.26409] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
18 Berentsen S, Hill A, Hill QA, Tvedt THA, Michel M. Novel insights into the treatment of complement-mediated hemolytic anemias. Ther Adv Hematol 2019;10:2040620719873321. [PMID: 31523413 DOI: 10.1177/2040620719873321] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
19 Rushing BR, Rohlik DL, Roy S, Skaff DA, Garcia BL. Targeting the Initiator Protease of the Classical Pathway of Complement Using Fragment-Based Drug Discovery. Molecules 2020;25:E4016. [PMID: 32899120 DOI: 10.3390/molecules25174016] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Su J, Bylsma LC, Jiang X, Morales Arias J, Jain N, Nordyke RJ. Healthcare resource utilization among commercially insured patients with cold agglutinin disease in the United States. Journal of Medical Economics 2020;23:902-7. [DOI: 10.1080/13696998.2020.1764006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
21 Fattizzo B, Giannotta JA, Cecchi N, Barcellini W. SARS-CoV-2 vaccination induces breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria on complement inhibitor. Am J Hematol 2021;96:E344-6. [PMID: 34057236 DOI: 10.1002/ajh.26262] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
22 Lau-Braunhut SA, Stone H, Collins G, Berentsen S, Braun BS, Zinter MS. Paroxysmal cold hemoglobinuria successfully treated with complement inhibition. Blood Adv 2019;3:3575-8. [PMID: 31738828 DOI: 10.1182/bloodadvances.2019000897] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
23 Vágó EK, Nicholson G, Horváth-Puhó E, Hooda N, Fryzek JP, Su J. Healthcare resource utilization among patients with cold agglutinin disease in Denmark. Curr Med Res Opin 2021;:1-7. [PMID: 34308723 DOI: 10.1080/03007995.2021.1960494] [Reference Citation Analysis]
24 Bizjak M, Košnik M, Terhorst-Molawi D, Dinevski D, Maurer M. Cold Agglutinins and Cryoglobulins Associate With Clinical and Laboratory Parameters of Cold Urticaria. Front Immunol 2021;12:665491. [PMID: 33995398 DOI: 10.3389/fimmu.2021.665491] [Cited by in F6Publishing: 1] [Reference Citation Analysis]